Drug Discovery Outsourcing Market (Workflow: Target Identification & Screening, Lead Identification & Candidate Optimization, Development of Disease Models, Pre-formulation Studies, Entire Clinical Trials, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Report | 2023-07-07 | 214 pages | Transparency Market Research

AVAILABLE LICENSES:

- Single User License $5795.00
- Multi User License $8795.00
- Global Site License $11795.00

Report description:

Drug Discovery Outsourcing Market - Scope of Report
TMR's report on the global drug discovery outsourcing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global drug discovery outsourcing market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug discovery outsourcing market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the drug discovery outsourcing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug discovery outsourcing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug discovery

outsourcing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug discovery outsourcing market.

The report delves into the competitive landscape of the global drug discovery outsourcing market. Key players operating in the global drug discovery outsourcing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug discovery outsourcing market profiled in this report.

Key Questions Answered in Global Drug Discovery Outsourcing Market Report
- What is the sales/revenue generated by drug discovery outsourcing across all regions during the forecast period?
- What are the opportunities in the global drug discovery outsourcing market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?

Drug Discovery Outsourcing Market - Research Objectives and Research Approach
The comprehensive report on the global drug discovery outsourcing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug discovery outsourcing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug discovery outsourcing market.

Table of Contents:

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug Discovery Outsourcing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints

4.3.3. Opportunities
4.4. Global Drug Discovery Outsourcing Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. Overview: Integrated Drug Discovery (IDD) outsourcing
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Chemistry Services
6.3.2. Biology Services
6.4. Market Attractiveness Analysis, by Type
7. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Drug Molecule
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Molecule, 2017-2031
7.3.1. Small Molecules
7.3.2. Large Molecules
7.4. Market Attractiveness Analysis, by Drug Molecule
8. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Discovery Approach
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Discovery Approach, 2017-2031
8.3.1. Empirical Drug Discovery
8.3.2. Rational Drug Discovery
8.4. Market Attractiveness Analysis, by Discovery Approach
9. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Therapeutic Area
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Therapeutic Area, 2017-2031
9.3.1. Anti-infective
9.3.2. Cardiovascular
9.3.3. Central Nervous System
9.3.4. Dermatology
9.3.5. Endocrine
9.3.6. Gastrointestinal
9.3.7. Genitourinary System
9.3.8. Immunomodulation
9.3.9. Oncology
9.3.10. Ophthalmology
9.3.11. Respiratory System
9.3.12. Others
9.4. Market Attractiveness Analysis, by Therapeutic Area
10. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Workflow
10.1. Introduction & Definition

10.2. Key Findings/Developments
10.3. Market Value Forecast, by Workflow, 2017-2031
10.3.1. Target Identification and Screening
10.3.2. Lead Identification and Candidate Optimization
10.3.3. Development of Disease Models
10.3.4. Pre-formulation Studies
10.3.5. Entire Clinical Trials
10.3.6. Others
10.4. Market Attractiveness Analysis, by Workflow
11. Global Drug Discovery Outsourcing Market Analysis and Forecast, by End-user
11.1. Introduction & Definition
11.2. Key Findings/Developments
11.3. Market Value Forecast, by Discovery Approach, 2017-2031
11.3.1. Pharmaceutical Companies
11.3.2. Biotechnology Companies
11.3.3. Academic Institutes
11.4. Market Attractiveness Analysis, by End-user
12. Global Drug Discovery Outsourcing Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region, 2017-2031
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness Analysis, by Region
13. North America Drug Discovery Outsourcing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
13.2.1. Chemistry Services
13.2.2. Biology Services
13.3. Market Value Forecast, by Drug Molecule, 2017-2031
13.3.1. Small Molecules
13.3.2. Large Molecules
13.4. Market Value Forecast, by Discovery Approach, 2017-2031
13.4.1. Empirical Drug Discovery
13.4.2. Rational Drug Discovery
13.5. Market Value Forecast, by Therapeutic Area, 2017-2031
13.5.1. Anti-infective
13.5.2. Cardiovascular
13.5.3. Central Nervous System
13.5.4. Dermatology
13.5.5. Endocrine
13.5.6. Gastrointestinal
13.5.7. Genitourinary System
13.5.8. Immunomodulation

13.5.9. Oncology
13.5.10. Ophthalmology
13.5.11. Respiratory System
13.5.12. Others
13.6. Market Value Forecast, by Workflow, 2017-2031
13.6.1. Target Identification and Screening
13.6.2. Lead Identification and Candidate Optimization
13.6.3. Development of Disease Models
13.6.4. Pre-formulation Studies
13.6.5. Entire Clinical Trials
13.6.6. Others
13.7. Market Value Forecast, by End-user, 2017-2031
13.7.1. Pharmaceutical Companies
13.7.2. Biotechnology Companies
13.7.3. Academic Institutes
13.8. Market Value Forecast, by Country, 2017-2031
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Type
13.9.2. By Drug Molecule
13.9.3. By Discovery Approach
13.9.4. By Therapeutic Area
13.9.5. By Workflow
13.9.6. By End-user
13.9.7. By Country
14. Europe Drug Discovery Outsourcing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
14.2.1. Chemistry Services
14.2.2. Biology Services
14.3. Market Value Forecast, by Drug Molecule, 2017-2031
14.3.1. Small Molecules
14.3.2. Large Molecules
14.4. Market Value Forecast, by Discovery Approach, 2017-2031
14.4.1. Empirical Drug Discovery
14.4.2. Rational Drug Discovery
14.5. Market Value Forecast, by Therapeutic Area, 2017-2031
14.5.1. Anti-infective
14.5.2. Cardiovascular
14.5.3. Central Nervous System
14.5.4. Dermatology
14.5.5. Endocrine
14.5.6. Gastrointestinal
14.5.7. Genitourinary System
14.5.8. Immunomodulation

14.5.9. Oncology
14.5.10. Ophthalmology
14.5.11. Respiratory System
14.5.12. Others
14.6. Market Value Forecast, by Workflow, 2017-2031
14.6.1. Target Identification and Screening
14.6.2. Lead Identification and Candidate Optimization
14.6.3. Development of Disease Models
14.6.4. Pre-formulation Studies
14.6.5. Entire Clinical Trials
14.6.6. Others
14.7. Market Value Forecast, by End-user, 2017-2031
14.7.1. Pharmaceutical Companies
14.7.2. Biotechnology Companies
14.7.3. Academic Institutes
14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Italy
14.8.5. Spain
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Type
14.9.2. By Drug Molecule
14.9.3. By Discovery Approach
14.9.4. By Therapeutic Area
14.9.5. By Workflow
14.9.6. By End-user
14.9.7. By Country/Sub-region
15. Asia Pacific Drug Discovery Outsourcing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017-2031
15.2.1. Chemistry Services
15.2.2. Biology Services
15.3. Market Value Forecast, by Drug Molecule, 2017-2031
15.3.1. Small Molecules
15.3.2. Large Molecules
15.4. Market Value Forecast, by Discovery Approach, 2017-2031
15.4.1. Empirical Drug Discovery
15.4.2. Rational Drug Discovery
15.5. Market Value Forecast, by Therapeutic Area, 2017-2031
15.5.1. Anti-infective
15.5.2. Cardiovascular
15.5.3. Central Nervous System
15.5.4. Dermatology

15.5.5. Endocrine
15.5.6. Gastrointestinal
15.5.7. Genitourinary System
15.5.8. Immunomodulation
15.5.9. Oncology
15.5.10. Ophthalmology
15.5.11. Respiratory System
15.5.12. Others
15.6. Market Value Forecast, by Workflow, 2017-2031
15.6.1. Target Identification and Screening
15.6.2. Lead Identification and Candidate Optimization
15.6.3. Development of Disease Models
15.6.4. Pre-formulation Studies
15.6.5. Entire Clinical Trials
15.6.6. Others
15.7. Market Value Forecast, by End-user, 2017-2031
15.7.1. Pharmaceutical Companies
15.7.2. Biotechnology Companies
15.7.3. Academic Institutes
15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Type
15.9.2. By Drug Molecule
15.9.3. By Discovery Approach
15.9.4. By Therapeutic Area
15.9.5. By Workflow
15.9.6. By End-user
15.9.7. By Country/Sub-region
16. Latin America Drug Discovery Outsourcing Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Type, 2017-2031
16.2.1. Chemistry Services
16.2.2. Biology Services
16.3. Market Value Forecast, by Drug Molecule, 2017-2031
16.3.1. Small Molecules
16.3.2. Large Molecules
16.4. Market Value Forecast, by Discovery Approach, 2017-2031
16.4.1. Empirical Drug Discovery
16.4.2. Rational Drug Discovery
16.5. Market Value Forecast, by Therapeutic Area, 2017-2031
16.5.1. Anti-infective

16.5.2. Cardiovascular
16.5.3. Central Nervous System
16.5.4. Dermatology
16.5.5. Endocrine
16.5.6. Gastrointestinal
16.5.7. Genitourinary System
16.5.8. Immunomodulation
16.5.9. Oncology
16.5.10. Ophthalmology
16.5.11. Respiratory System
16.5.12. Others
16.6. Market Value Forecast, by Workflow, 2017-2031
16.6.1. Target Identification and Screening
16.6.2. Lead Identification and Candidate Optimization
16.6.3. Development of Disease Models
16.6.4. Pre-formulation Studies
16.6.5. Entire Clinical Trials
16.6.6. Others
16.7. Market Value Forecast, by End-user, 2017-2031
16.7.1. Pharmaceutical Companies
16.7.2. Biotechnology Companies
16.7.3. Academic Institutes
16.8. Market Value Forecast, by Country/Sub-region, 2017-2031
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Type
16.9.2. By Drug Molecule
16.9.3. By Discovery Approach
16.9.4. By Therapeutic Area
16.9.5. By Workflow
16.9.6. By End-user
16.9.7. By Country/Sub-region
17. Middle East & Africa Drug Discovery Outsourcing Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Type, 2017-2031
17.2.1. Chemistry Services
17.2.2. Biology Services
17.3. Market Value Forecast, by Drug Molecule, 2017-2031
17.3.1. Small Molecules
17.3.2. Large Molecules
17.4. Market Value Forecast, by Discovery Approach, 2017-2031
17.4.1. Empirical Drug Discovery
17.4.2. Rational Drug Discovery
17.5. Market Value Forecast, by Therapeutic Area, 2017-2031

17.5.1. Anti-infective
17.5.2. Cardiovascular
17.5.3. Central Nervous System
17.5.4. Dermatology
17.5.5. Endocrine
17.5.6. Gastrointestinal
17.5.7. Genitourinary System
17.5.8. Immunomodulation
17.5.9. Oncology
17.5.10. Ophthalmology
17.5.11. Respiratory System
17.5.12. Others
17.6. Market Value Forecast, by Workflow, 2017-2031
17.6.1. Target Identification and Screening
17.6.2. Lead Identification and Candidate Optimization
17.6.3. Development of Disease Models
17.6.4. Pre-formulation Studies
17.6.5. Entire Clinical Trials
17.6.6. Others
17.7. Market Value Forecast, by End-user, 2017-2031
17.7.1. Pharmaceutical Companies
17.7.2. Biotechnology Companies
17.7.3. Academic Institutes
17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of MEA
17.9. Market Attractiveness Analysis
17.9.1. By Type
17.9.2. By Drug Molecule
17.9.3. By Discovery Approach
17.9.4. By Therapeutic Area
17.9.5. By Workflow
17.9.6. By End-user
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player - Competitive Matrix (by tier and size of companies)
18.2. Market Share Analysis, by Company (2022)
18.3. Company Profiles
18.3.1. Charles River Laboratories International, Inc.
18.3.1.1. Company Overview
18.3.1.2. Product Portfolio
18.3.1.3. SWOT Analysis
18.3.1.4. Financial Overview
18.3.1.5. Strategic Overview
18.3.2. WuXi AppTec Co., Ltd.
18.3.2.1. Company Overview

18.3.2.2. Product Portfolio
18.3.2.3. SWOT Analysis
18.3.2.4. Financial Overview
18.3.2.5. Strategic Overview
18.3.3. Albany Molecular Research Inc.
18.3.3.1. Company Overview
18.3.3.2. Product Portfolio
18.3.3.3. SWOT Analysis
18.3.3.4. Financial Overview
18.3.3.5. Strategic Overview
18.3.4. GVK Biosciences Private Limited
18.3.4.1. Company Overview
18.3.4.2. Product Portfolio
18.3.4.3. SWOT Analysis
18.3.4.4. Financial Overview
18.3.4.5. Strategic Overview
18.3.5. Sygnature Discovery
18.3.5.1. Company Overview
18.3.5.2. Product Portfolio
18.3.5.3. SWOT Analysis
18.3.5.4. Financial Overview
18.3.5.5. Strategic Overview
18.3.6. Pharmaron Beijing Co., Ltd.
18.3.6.1. Company Overview
18.3.6.2. Product Portfolio
18.3.6.3. SWOT Analysis
18.3.6.4. Financial Overview
18.3.6.5. Strategic Overview
18.3.7. Domainex Ltd.
18.3.7.1. Company Overview
18.3.7.2. Product Portfolio
18.3.7.3. SWOT Analysis
18.3.7.4. Financial Overview
18.3.7.5. Strategic Overview
18.3.8. Thermo Fisher Scientific, Inc.
18.3.8.1. Company Overview
18.3.8.2. Product Portfolio
18.3.8.3. SWOT Analysis
18.3.8.4. Financial Overview
18.3.8.5. Strategic Overview
18.3.9. Jubilant Biosys Ltd.
18.3.9.1. Company Overview
18.3.9.2. Product Portfolio
18.3.9.3. SWOT Analysis
18.3.9.4. Financial Overview
18.3.9.5. Strategic Overview
18.3.10. Evotec SE

18.3.10.1. Company Overview
18.3.10.2. Product Portfolio
18.3.10.3. SWOT Analysis
18.3.10.4. Financial Overview
18.3.10.5. Strategic Overview
18.3.11. Eurofins Discovery
18.3.11.1. Company Overview
18.3.11.2. Product Portfolio
18.3.11.3. SWOT Analysis
18.3.11.4. Financial Overview
18.3.11.5. Strategic Overview
18.3.12. GenScript Biotech Corporation
18.3.12.1. Company Overview
18.3.12.2. Product Portfolio
18.3.12.3. SWOT Analysis
18.3.12.4. Financial Overview
18.3.12.5. Strategic Overview

Drug Discovery Outsourcing Market (Workflow: Target Identification & Screening, Lead Identification & Candidate Optimization, Development of Disease Models, Pre-formulation Studies, Entire Clinical Trials, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Report | 2023-07-07 | 214 pages | Transparency Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$5795.00
	Multi User License	$8795.00
	Global Site License	$11795.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	

Date	2025-06-24
Signature	